Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

BACKGROUND: Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed and refractory (R/R) setting, but once discontinued owing to progression or side effects, it is unclear how successful further therapies will be. Moreover,...

詳細記述

保存先:
書誌詳細
出版年:Oncologist
主要な著者: Carreau, Nicole A., Pail, Orrin, Armand, Philippe, Merryman, Reid, Advani, Ranjana H., Spinner, Michael A., Herrera, Alex, Chen, Robert, Tomassetti, Sarah, Ramchandren, Radhakrishnan, Hamid, Muhammad S., Assouline, Sarit, Santiago, Raoul, Wagner‐Johnston, Nina, Paul, Suman, Svoboda, Jakub, Bair, Steven, Barta, Stefan, Liu, Yang, Nathan, Sunita, Karmali, Reem, Burkart, Madelyn, Torka, Pallawi, David, Kevin, Wei, Catherine, Lansigan, Frederick, Emery, Lukas, Persky, Daniel, Smith, Sonali, Godfrey, James, Chavez, Julio, Xia, Yuhe, Troxel, Andrea B., Diefenbach, Catherine
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Inc. 2020
主題:
Hematologic Malignancies
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7543382/
https://ncbi.nlm.nih.gov/pubmed/32720734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0167
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料